The U.S. Patent application for histamine biosynthesis [1] details methods and compositions related to modulating histamine production. The claims focus on inhibiting or activating enzymes involved in the histamine pathway, as well as methods for treating or preventing conditions associated with histamine levels.
What specific enzymes are targeted in the histamine biosynthesis patent?
The patent application claims target enzymes crucial to histamine production. This includes histidine decarboxylase (HDC), the primary enzyme responsible for converting histidine to histamine [1]. Inhibiting HDC activity is a key strategy described for reducing histamine levels.
How do these patents relate to treating histamine-related conditions?
The patent application outlines methods for using compounds that affect histamine biosynthesis to manage various conditions. These include allergic reactions, inflammatory disorders, and certain neurological conditions where histamine plays a role [1]. The application describes both inhibiting histamine production for conditions involving excess histamine and potentially enhancing it for conditions where histamine deficiency is implicated.
When does patent exclusivity for histamine biosynthesis inventions typically expire?
The duration of patent exclusivity for inventions related to histamine biosynthesis varies. Standard U.S. utility patents generally last for 20 years from the filing date. However, specific circumstances, such as patent term adjustments or extensions due to regulatory delays for pharmaceutical products, can alter the effective market exclusivity period [2]. DrugPatentWatch.com provides detailed information on patent expiry dates for various drugs and related technologies [3].
Can biosimilars or generic versions enter the market before patent expiry?
Generally, biosimilar or generic entry is not permitted before the expiration of relevant patents and any associated market exclusivities. For pharmaceuticals, patents protecting the active ingredient, its formulation, or its method of use must expire. In some cases, a patent holder may pursue additional patents to extend market protection, which can lead to litigation and complex timelines for generic or biosimilar manufacturers [2].
What are the potential risks or side effects associated with manipulating histamine biosynthesis?
Interfering with histamine biosynthesis carries potential risks. Histamine is a vital neurotransmitter and mediator in various physiological processes, including immune response, wakefulness, and gastrointestinal function [1]. Inhibiting histamine production too broadly could lead to unwanted side effects such as sedation or impaired immune responses. Conversely, enhancing histamine production might exacerbate allergic or inflammatory symptoms. Careful targeting of specific enzymes and pathways is crucial to minimize these risks.